Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Moreno-Arrones, Oscar M.
• dc.contributor.author Deza Vargas, Luis Gustavo
• dc.contributor.author Sanmartin, Onofre
• dc.date.accessioned 2024-02-20T07:29:28Z
• dc.date.available 2024-02-20T07:29:28Z
• dc.date.issued 2023
• dc.description Article disponible en castellà: http://hdl.handle.net/10230/59175
• dc.description.abstract Background: Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. Objective: To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile. Methods: We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected. Results: A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24h and 48h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. Conclusion: Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice.
• dc.format.mimetype application/pdf
• dc.identifier.citation Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M et al. Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study. Actas Dermosifiliogr. 2023 Jul-Aug;114(7):565-71. DOI: 10.1016/j.ad.2023.04.022
• dc.identifier.doi http://dx.doi.org/10.1016/j.ad.2023.04.022
• dc.identifier.issn 0001-7310
• dc.identifier.uri http://hdl.handle.net/10230/59174
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Actas Dermosifiliogr. 2023 Jul-Aug;114(7):565-71
• dc.rights © 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Cutaneous neoplasms
• dc.subject.keyword Cutaneous oncology
• dc.subject.keyword Dermatology therapy
• dc.subject.keyword Oncology
• dc.title Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion